DAPA-CKD Resets eGFR Ground for Safe SGLT2 Inhibitor Use

DAPA-CKD Resets eGFR Ground for Safe SGLT2 Inhibitor Use

The dramatically particular safety and efficacy outcomes from the DAPA-CKD trial, which showed that treatment with the sodium-glucose transporter 2 (SGLT2) inhibitor dapagliflozin vastly reduce back each chronic kidney disease development and all-cause loss of life in patients with or…